Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Neural Regulation01:37

Neural Regulation

40.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

454
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
454
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.8K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.8K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.0K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.0K
Gene Therapy00:59

Gene Therapy

26.3K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
26.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Construct optimization for AAV-mediated human α-syn overexpression, and validation across research settings: Development of a shared tool for the research community.

Journal of Parkinson's disease·2026
Same author

Effects of chemogenetic inhibition of serotonergic raphe-striatal neurons on L-DOPA-induced behaviors and neurochemistry in a rat model of Parkinson's disease.

Acta neuropathologica communications·2026
Same author

Tau, amyloid-β and α-synuclein co-pathologies synergistically enhance neuroinflammation and hippocampal neuron loss.

Neurobiology of disease·2026
Same author

Correction: MHCII reduction is insufficient to protect mice from alpha-synuclein-induced degeneration and the Parkinson's HLA locus exhibits epigenetic regulation.

Scientific reports·2025
Same author

Gene therapy for Parkinson's disease-Ample room for optimism.

Current opinion in neurobiology·2025
Same author

Tau, amyloid-β and α-synuclein co-pathologies synergistically enhance neuroinflammation and neuropathology.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Nov 3, 2025

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.4K

Gene Therapy to Modulate Alpha-Synuclein in Synucleinopathies.

Ivette M Sandoval1, David J Marmion1, Kimberly T Meyers1

  • 1Department of Neurobiology, Barrow Neurological Institute, Phoenix, AZ, USA.

Journal of Parkinson'S Disease
|June 7, 2021
PubMed
Summary

Gene therapy offers potential interventions for Parkinson's disease (PD) by targeting alpha-Synuclein (α-Syn) toxicity. This review explores preclinical gene therapy strategies to reduce neurodegeneration caused by α-Syn.

Keywords:
Parkinson’s diseasealpha-synucleingene therapylewy pathologysynucleinopathies

More Related Videos

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
12:01

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

10.9K
Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector
08:33

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Published on: February 28, 2016

13.5K

Related Experiment Videos

Last Updated: Nov 3, 2025

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.4K
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
12:01

Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein

Published on: May 30, 2015

10.9K
Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector
08:33

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Published on: February 28, 2016

13.5K

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Alpha-Synuclein (α-Syn) aggregation and spread are central to Parkinson's disease (PD) pathogenesis.
  • Neurodegeneration in PD involves complex, multifactorial processes including α-Syn dose, autophagy-lysosomal dysfunction, and inflammation.

Purpose of the Study:

  • To identify strategic intervention points for gene therapy in α-Syn-mediated Parkinson's disease.
  • To review existing and conceptual preclinical gene therapy approaches for ameliorating α-Syn induced neurotoxicity.

Main Methods:

  • Review of preclinical studies utilizing gene therapy for Parkinson's disease.
  • Discussion of gene expression modulation via traditional methods.
  • Exploration of viral vectors and nanoparticles for therapeutic delivery.

Main Results:

  • Gene therapy presents logical intervention points within the α-Syn pathway in PD.
  • Preclinical evidence supports the potential of gene therapy to mitigate α-Syn neurotoxicity.
  • Diverse delivery methods, including viral vectors and nanoparticles, are being investigated.

Conclusions:

  • Gene therapy holds significant promise as a therapeutic strategy for Parkinson's disease.
  • Targeting α-Syn through gene modulation offers a viable approach to combat PD neurodegeneration.
  • Further preclinical research is essential to optimize gene therapy delivery and efficacy for PD treatment.